Seeking Alpha
 

Baxter International Inc (BAX)

- NYSE
  • Jul. 2, 2013, 8:46 AM
    Baxter (BAX) presents the results of two studies that confirm the safety and efficacy of the company's approved Advate drug for hemophilia A. One post-marketing analysis, which looked at 1,200 patients in 15 countries, supports Advate's low inhibitor rate and the effectiveness of its bleed prevention. The other research, an analysis of 12 clinical trials, affirmed the drug's safety profile. (PR)
    | Comment!
  • Jun. 27, 2013, 9:33 AM
    The FDA approves Baxter's (BAX +0.3%) Rixubis treatment for adults with hemophilia B, including for use as a preventative measure, for control of bleeding episodes, and for perioperative management, when patients are having surgery. (PR)
    | Comment!
  • Jun. 24, 2013, 2:20 PM
    Neostem (NBS +5.7%) gets a boost from an upgrade at Aegis Capital with a Buy rating and a $2.50 price target. Aegis says NBS represents a unique participant in the stem cell sector, given the fact that it has four different technology platforms and a solid lead product candidate, AMR-001, which is a stem cell-based therapeutic for cardiovascular disease with tremendous potential. The drug is currently in a proof-of-concept Phase 2 trial that is slated to report data early next year, and positive results could land it a partnership with Baxter (BAX).
    | 2 Comments
  • Jun. 11, 2013, 11:36 AM
    UBS suggests 11 dividend growing stocks to buy for income; each has a dividend yield of at least 2.5%, has increased its payout ratio by more than 5% during the past year, and has positive consensus EPS growth over the next 12 months: WMB, ESV, NUE, JNJ, CAG, KLAC, CSCO, BBT, AAPL, BAX, F.
    | 2 Comments
  • May. 7, 2013, 1:54 PM
    Barclays comes to the defense of Baxter (BAX -3.1%) this afternoon, upping the stock to Overweight on today's weakness. The stock was hit after the drug-maker said Phase III testing of its Gammagard treatment for Alzheimer's disease did not meet its co-primary endpoints.
    | Comment!
  • May. 7, 2013, 8:25 AM
    Baxter International (BAX) slips 2.2% premarket after Phase III testing on its Alzheimer's drug immunoglobulin (IG) - always a long shot - failed to meet its co-primary endpoints. (PR)
    | 1 Comment
  • May. 7, 2013, 6:21 AM
    Baxter International (BAX) declares $0.49/share quarterly dividend, 9% increase from prior dividend of $0.45. Forward yield 2.56%. For shareholders of record June 07. Payable July 01. Ex-div date June 05. (PR)
    | Comment!
  • May. 6, 2013, 7:02 AM
    Vical (VICL) says the addition of its Vaxfectin adjuvant to Baxter's (BAX) influenza vaccines "substantially increases both antibody and T-cell responses." VICL's VP of vaccine research says seasonal influenza vaccines sometimes underperform in elderly patients — "a good adjuvant could" help, he adds. (PR)
    | Comment!
  • Apr. 26, 2013, 3:42 PM
    Looking for dividend picks, Marketwatch screens the S&P 1,500 for 1) Stock trades at less than a 17x PE 2) Dividend yield 20% or more higher than S&P 500 3) Raised dividend at least 5 times in last 5 years 4) S&P Quality Rank of B+ or better. The winners: T, AVA, BAX, CAH, CAG, ED, JNJ, LG, TAP, RAI, SCG, UVV, WR, XEL.
    | 1 Comment
  • Apr. 18, 2013, 9:03 AM
    More on Baxter (BAX) Q1: net profit -11% to $552M, dragged down by charges related to its purchase of Gambrro, while last year's figures included a tax benefit. Medical-products sales -0.4% to $1.92B, BioScience revenue +4.7% to $1.53B. Expects sales growth of 4% in Q2 and 10% for FY; forecasts EPS of Q2 EPS of $1.12-1.14 vs consensus of $1.14 and 2014 EPS of $4.60-4.70 vs 4.66. (PR)
    | Comment!
  • Apr. 18, 2013, 7:03 AM
    Baxter (BAX): Q1 EPS of $1.05 in-line. Revenue of $3.45B (+2% Y/Y) misses by $0.04B. (PR)
    | Comment!
  • Apr. 18, 2013, 12:05 AM
    Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ
    | Comment!
  • Apr. 17, 2013, 5:30 PM
    Notable earnings before Thursday’s open: ADS, AN, APH, BAX, BBT, BPOP, BTU, BX, CY, DHR, FCS, FCX, FITB, KEY, LDK, MMR, MS, NOK, NUE, OMC, PBCT, PENN, PEP, PM, PPG, SHW, SNA, SON, TSM, TZOO, UNH, UNP, VZ
    | Comment!
  • Apr. 4, 2013, 4:45 AM
    The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK).
    | 5 Comments
  • Mar. 22, 2013, 9:29 AM
    Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year.
    | Comment!
  • Feb. 19, 2013, 9:35 AM
    Baxter International Inc. (BAX) declares $0.45/share quarterly dividend, in line with previous. Forward yield 2.64%. For shareholders of record Mar. 08. Payable Apr. 01. Ex-div date Mar. 06. (PR)
    | Comment!
Visit Seeking Alpha's
BAX vs. ETF Alternatives
Company Description
Baxter International Inc is a healthcare company. It develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma and other chronic conditions.